GlassScriptPhysician profile
Sanjay R Parikh
NPI 1073588414
$97,834.73
in general payments reported to CMS, 2019-2025
41 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $8,033 · 2021: $18K · 2022: $4,501 · 2023: $19K · 2024: $14K · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $7,700 · Food and Beverage: $4,771 · Travel and Lodging: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,210.00 |
| Consulting Fee | $7,700.00 |
| Food and Beverage | $4,770.69 |
| Travel and Lodging | $2,376.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $38,919.53 | 2019-2024 | Jornay Pm |
| Corium, LLC | $27,885.77 | 2022-2025 | Azstarys, Azstarys |
| Tris Pharma INC | $14,077.05 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $11,476.23 | 2019-2025 | Qelbree, Qelbree |
| Abbvie INC. | $778.62 | 2021-2025 | |
| Ucb, INC. | $745.39 | 2019-2025 | Briviact, Nayzilam |
| Lilly USA, LLC | $494.17 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Teva Pharmaceuticals USA, INC. | $427.52 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurelis, INC. | $354.09 | 2020-2025 | Valtoco |
| Neos Therapeutics, LP | $306.17 | 2019-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $258.36 | 2019-2025 | Hyqvia |
| Neurocrine Biosciences, INC. | $250.24 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $146.16 | 2019-2025 | Vyepti |
| Pfizer INC. | $145.25 | 2023-2025 | |
| Amgen INC. | $131.52 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.